List of Excipients in Branded Drug FLUOCINONIDE GEL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alvogen Inc	FLUOCINONIDE GEL	fluocinonide gel	47781-533	CARBOMER HOMOPOLYMER TYPE C
Alvogen Inc	FLUOCINONIDE GEL	fluocinonide gel	47781-533	EDETATE DISODIUM
Alvogen Inc	FLUOCINONIDE GEL	fluocinonide gel	47781-533	PROPYL GALLATE
Alvogen Inc	FLUOCINONIDE GEL	fluocinonide gel	47781-533	PROPYLENE GLYCOL

Generic Drugs Containing FLUOCINONIDE GEL

Company	Ingredient	NDC	Excipient
SOLA Pharmaceuticals	fluocinonide gel	70512-034	CARBOMER HOMOPOLYMER TYPE C
SOLA Pharmaceuticals	fluocinonide gel	70512-034	EDETATE DISODIUM
SOLA Pharmaceuticals	fluocinonide gel	70512-034	PROPYL GALLATE
SOLA Pharmaceuticals	fluocinonide gel	70512-034	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in FLUOCINONIDE GEL?

# Of NDCs	Excipient
1	CARBOMER HOMOPOLYMER TYPE C
1	EDETATE DISODIUM
1	PROPYL GALLATE
1	PROPYLENE GLYCOL

Fluocinide Gel Excipient Strategy and Commercial Opportunities

Last updated: November 8, 2026

Fluocinide gel 0.05% is a high-potency topical corticosteroid with limited active-ingredient differentiation. Its commercial opportunity is concentrated in excipient optimization, tolerability, packaging, adherence, and differentiated delivery rather than new-molecule exclusivity. The most credible product concepts are alcohol-reduced or alcohol-free gels, propylene-glycol-free systems, low-irritancy vehicles, metered-dose packaging, and new topical dosage forms supported by clinical or pharmacokinetic data.

What is fluocinide gel and how is it regulated?

Fluocinide gel contains fluocinonide, a synthetic corticosteroid used for inflammatory and pruritic corticosteroid-responsive dermatoses. The gel is generally labeled at a 0.05% strength and is classified as a high-potency topical corticosteroid.[1]

Fluocinide gel is a prescription drug. It is not a biologic, so biosimilar regulation does not apply. Generic competition proceeds through the abbreviated new drug application, or ANDA, pathway, while a materially different dosage form, delivery system, or clinical positioning may require a 505(b)(2) application.

Attribute	Fluocinide gel
Active ingredient	Fluocinide, also known as fluocinonide
Typical strength	0.05%
Dosage form	Topical gel
Therapeutic class	High-potency corticosteroid
Regulatory category	Prescription drug
Generic pathway	ANDA for pharmaceutically equivalent product
Potential differentiated pathway	505(b)(2) for a new formulation, delivery system, or clinical use
Biosimilar exposure	Not applicable
Primary commercial buyers	Retail pharmacies, specialty dermatology practices, managed-care plans, wholesalers

The high potency creates a narrow risk-benefit window. Product differentiation must improve application, tolerability, cosmetic acceptability, adherence, or delivery without increasing systemic absorption or local adverse effects.

What excipients are used in fluocinide gel?

Commercial fluocinide gel formulations typically use a hydroalcoholic gel vehicle containing a gelling polymer, humectant or cosolvent, water, and a pH-adjusting agent. Product labels identify inactive ingredients such as carbomer-type polymers, alcohol, propylene glycol, purified water, and sodium hydroxide, although the exact composition varies by manufacturer.[2][3]

A representative excipient architecture is:

Functional role	Common excipient class	Commercial function
Gel former	Carbomer or related acrylic polymer	Viscosity, suspension, residence time
Solvent	Alcohol, often ethanol	Fluocinonide solubilization, rapid drying
Cosolvent and humectant	Propylene glycol	Solubility, moisturization, skin penetration
Vehicle	Purified water	Continuous phase
Neutralizer	Sodium hydroxide or equivalent	Carbomer swelling and pH adjustment
Optional stabilizer	Chelator or antioxidant, where justified	Protection against degradation
Packaging support	Tube or pump-compatible formulation	Dose control and product stability

The excipient system is central to product performance. Fluocinide is a potent corticosteroid, so a formulation does not need aggressive penetration enhancement to achieve pharmacologic activity. Excessive solvent content or penetration enhancement can increase irritation and systemic exposure without creating a compelling clinical advantage.

What is the role of alcohol in fluocinide gel?

Alcohol can improve solubilization and evaporation. It creates a light, fast-drying product that may be acceptable on hairy or oily skin. Its disadvantages include stinging on fissured or inflamed skin, increased dryness, and lower acceptability for patients with sensitive skin.

An alcohol-containing gel may perform well for short-duration treatment of localized plaques where rapid drying is valuable. It is less attractive for chronic relapsing disease, excoriated skin, pediatric use, or patients with a history of irritant reactions.

What is the role of propylene glycol?

Propylene glycol can act as a cosolvent, humectant, and penetration-enhancing excipient. It can improve fluocinide solubilization and contribute to drug release from the gel matrix.

Its principal commercial weakness is tolerability. Propylene glycol can cause irritant or allergic contact dermatitis in susceptible patients. A propylene-glycol-free formulation could create a credible differentiation strategy, especially if it demonstrates comparable release and skin delivery.

Which excipient strategies have the strongest commercial potential?

The highest-value strategy is not simply replacing one excipient. The formulation must preserve drug release, content uniformity, stability, viscosity, microbiological quality, and skin delivery while solving a recognized patient or prescriber problem.

Strategy	Patient benefit	Technical risk	Commercial potential
Propylene-glycol-free gel	Reduced contact-dermatitis concern	Solubility and release changes	High
Alcohol-free gel	Less stinging and dryness	Drug solubilization, microbial control	High
Low-alcohol gel	Improved tolerability with fast drying	Balance between evaporation and release	Moderate to high
Nonionic polymer gel	Reduced sensitivity to pH and electrolytes	Rheology and suspension stability	Moderate
Emollient gel	Better skin feel and reduced dryness	Greasiness and slower drying	Moderate
Pump or metered-dose gel	Improved dosing and reduced contamination	Device compatibility and cost	Moderate
Film-forming gel	Longer residence time and fewer applications	Occlusion and increased exposure	Selective
Foaming or mousse system	Better spreadability on scalp or hairy skin	New-device and clinical requirements	Moderate
Mucoadhesive or specialized gel	Site-specific retention	Higher development and regulatory burden	Low to moderate

Is an alcohol-free fluocinide gel commercially attractive?

Yes, but the opportunity depends on whether the formulation retains the handling advantages of a gel. An alcohol-free product may reduce stinging and dryness, but it can become tacky, slow to dry, or cosmetically unacceptable. A water-rich system also requires robust preservative and microbiological-control design.

A successful alcohol-free platform would need:

• Comparable fluocinide release and skin permeation.
• Acceptable viscosity across storage temperatures.
• Low tack and rapid rub-in.
• Preservative effectiveness under applicable pharmacopeial testing.
• Packaging that limits microbial ingress.
• Stability data supporting commercial shelf life.

An alcohol-free gel could compete against conventional gels, creams, and ointments by targeting patients who discontinue hydroalcoholic products because of burning or dryness.

Is a propylene-glycol-free formulation attractive?

A propylene-glycol-free product is one of the clearest excipient-led opportunities. The formulation challenge is that removing propylene glycol can reduce fluocinide solubility and alter thermodynamic activity, drug release, and skin partitioning.

Potential replacement approaches include:

• Polyethylene glycol systems.
• Glycerin or other polyols.
• Transcutol-type cosolvents, subject to regulatory and tolerability review.
• Solubilizing surfactants at low concentrations.
• Alternative carbomer or acrylate polymers.
• Microemulsion or nanoemulsion systems.
• Drug-loaded polymeric dispersions.

The commercial claim should remain precise. "Propylene-glycol-free" is a formulation attribute, not proof of superior safety. Clinical relevance would be stronger if supported by irritation testing, repeat-use tolerability, or use in patients with documented excipient sensitivity.

What formulations are protected by fluocinide gel patents?

Historical fluocinide and topical corticosteroid patent protection is generally expired or commercially weak. The active ingredient has been marketed for decades, and conventional gel compositions using well-known carbomer, alcohol, water, and propylene glycol systems are unlikely to provide meaningful current exclusivity by themselves.

Current protection would more likely arise from:

1. A novel polymer or solvent system.
2. A specific combination of excipients with demonstrated performance.
3. A drug-delivery device integrated with the formulation.
4. A new dosage form, such as foam, spray, film-forming gel, or metered-dose system.
5. A method of treatment directed to a defined patient population or body site.
6. Manufacturing controls that produce a distinctive microstructure or release profile.

A patent directed only to substituting one conventional cosolvent for another would face substantial obviousness risk. Stronger claims would require comparative data showing an unexpected property, such as materially improved stability, reduced irritation with maintained delivery, or a clinically meaningful reduction in application frequency.

When does fluocinide gel lose exclusivity?

Fluocinide gel has no meaningful new-molecule exclusivity remaining. FDA approval of topical fluocinide products dates to the twentieth century, and the commercial market is populated by generic products.[1][4]

Exclusivity category	Status
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Biologic exclusivity	Not applicable
Conventional formulation exclusivity	Historical rights generally expired
Current commercial protection	Potentially limited to formulation, device, method, trademark, or manufacturing patents
Generic entry route	ANDA, subject to reference-product and product-specific requirements

A new formulation may obtain three years of FDA exclusivity if it relies on qualifying new clinical investigations essential to approval under the 505(b)(2) pathway. That exclusivity would protect the approved change, not the underlying fluocinide molecule.

What is the Orange Book status of fluocinide gel?

The Orange Book is relevant to approved prescription products and listed patents, but the status of individual fluocinide gel products can change as applications are withdrawn, discontinued, or updated.[4] Conventional generic fluocinide gel products do not generally have a current commercial moat based on active-ingredient patents.

For an ANDA launch, the practical issues are:

• Identifying the current reference listed drug.
• Confirming dosage-form and strength equivalence.
• Reviewing any patents or exclusivity associated with the reference product.
• Assessing whether formulation differences require a suitability petition or 505(b)(2) strategy.
• Preparing a Paragraph IV certification if a listed patent remains relevant.

A formulation that changes the vehicle, delivery device, or clinical indication may fall outside a simple ANDA strategy. The regulatory route depends on whether the product remains pharmaceutically equivalent and therapeutically equivalent to the reference product.

Which companies are challenging fluocinide gel exclusivity?

Generic manufacturers have competed in topical fluocinide products for many years. The competitive field typically includes large generic companies, regional dermatology suppliers, contract manufacturers, and private-label distributors.

No biosimilar challengers are relevant because fluocinide is a small-molecule corticosteroid. Paragraph IV activity is also less likely to be commercially significant for an old conventional gel than for a recently approved branded dermatology product. A Paragraph IV filing would become relevant if a new formulation or device patent created a meaningful commercial barrier.

For a conventional 0.05% gel, competition is more likely to focus on:

• Wholesale acquisition cost.
• Pharmacy substitution.
• Product availability.
• Tube size and packaging.
• Formulation tolerability.
• Retail and payer contracting.
• Manufacturing reliability.

What patent litigation affects fluocinide gel?

Fluocinide gel is not generally associated with an active, high-value patent litigation profile comparable to newer branded dermatology drugs. Historical litigation involving topical corticosteroids has tended to concern formulation patents, infringement of generic products, ANDA certifications, or product liability rather than durable molecule-level protection.

A new commercial entrant should evaluate:

Risk area	Relevance
Active ingredient patent	Low for fluocinide
Conventional gel composition	Low to moderate, depending on claim scope
Device patent	Moderate for metered-dose or specialized applicators
Method-of-use patent	Moderate if tied to a specific population or regimen
Trade dress and trademark	Moderate for branded launch
Manufacturing process	Moderate where process controls produce a claimed product profile
Trade secret	Relevant to scale-up and polymer processing

The highest litigation risk may come from a newly developed formulation patent rather than legacy fluocinide patents. Patent claims should be drafted around measurable formulation parameters, release behavior, microstructure, device integration, and validated clinical performance.

What manufacturing and intellectual-property barriers exist?

The principal technical barrier is controlling fluocinide distribution at low concentration. A 0.05% product contains a small amount of active ingredient, so mixing, polymer hydration, deaeration, and filling controls directly affect content uniformity and dose reproducibility.

Important development controls include:

• Uniform drug dispersion or solution state.
• Carbomer hydration and neutralization.
• Control of pH and viscosity.
• Prevention of air entrapment.
• Compatibility with tube, pump, or applicator materials.
• Preservative effectiveness.
• Stability under temperature cycling.
• Low extractables and leachables.
• Consistent fill weight and dose delivery.

Manufacturing know-how may support a trade-secret position, but trade secrets do not block a competitor using an independent process. Patent protection is stronger when the process creates a distinctive, measurable product attribute.

How does fluocinide gel compare with creams, ointments, and solutions?

Dosage form	Main advantage	Main limitation	Best commercial positioning
Gel	Fast drying, low residue, useful on hairy skin	Alcohol sting, dryness, tack	Scalp, hairy areas, localized plaques
Cream	Balanced feel and hydration	Less suitable for very hairy areas	General outpatient dermatology
Ointment	Occlusion and hydration	Greasy, poor cosmetic acceptability	Thick, dry, hyperkeratotic lesions
Solution	Easy scalp application	Dries skin and may sting	Scalp and hair-bearing sites
Foam or mousse	Spreadability and cosmetic appeal	Device and formulation cost	Scalp and large surface areas
Spray	Contact-minimized application	Dose control and inhalation concerns	Hard-to-reach sites

A differentiated gel should target a specific weakness of existing dosage forms. "Improved gel" is weak positioning. "Propylene-glycol-free gel for patients with excipient sensitivity" or "metered-dose scalp gel with reduced residue" is more commercially actionable.

What generic launch scenarios exist?

Conventional ANDA launch

A standard generic gel can reach market with the lowest development burden if it matches the reference product in active ingredient, strength, dosage form, route, and relevant pharmaceutical characteristics. The downside is rapid price erosion and limited differentiation.

Differentiated generic

A generic manufacturer can use a modified excipient system, packaging configuration, or preservative profile while maintaining pharmaceutical equivalence. This approach may improve tolerability and supply reliability but must avoid changes that trigger a more complex regulatory pathway.

505(b)(2) product

A 505(b)(2) strategy is appropriate for a new formulation or dosage form supported by clinical or pharmacokinetic evidence. Examples include an alcohol-free gel, foam, spray, or device-controlled delivery system. The investment is higher, but the product may support branded pricing and a period of regulatory exclusivity.

Specialty dermatology brand

A branded product can compete through sampling, dermatologist education, adherence packaging, payer contracting, and a focused excipient claim. This model requires evidence that the formulation solves a practical problem rather than simply changing inactive ingredients.

What commercial opportunity exists in fluocinide gel?

The addressable opportunity is primarily an erosion-resistant niche rather than a broad molecule-expansion opportunity.

The strongest concepts are:

1. A propylene-glycol-free gel for patients with suspected or documented contact sensitivity.
2. An alcohol-free or low-alcohol gel for inflamed or fissured skin.
3. A metered-dose scalp gel that improves dose consistency and reduces product waste.
4. A cosmetically elegant gel for hair-bearing areas.
5. A formulation with improved stability and supply reliability for generic or private-label channels.
6. A combination product, subject to clinical and regulatory support, targeting inflammatory dermatoses with a defined treatment need.

Revenue exposure for a conventional fluocinide gel is likely to be modest per product because multiple generics constrain pricing. A differentiated 505(b)(2) product could generate higher gross margin, but clinical development, formulation work, device validation, and market access costs would materially increase the investment requirement.

Key Takeaways

• Fluocinide gel 0.05% is an old, high-potency topical corticosteroid with no meaningful new-molecule exclusivity.
• Conventional gel excipients commonly include carbomer-type polymers, alcohol, propylene glycol, purified water, and a neutralizer.
• The most credible excipient opportunities are propylene-glycol-free, alcohol-free, low-irritancy, and metered-dose formulations.
• Conventional composition changes are unlikely to create durable patent value without comparative performance data.
• Biosimilar competition does not apply; generic competition is the principal market risk.
• An ANDA is the lowest-cost pathway for a conventional equivalent. A 505(b)(2) application may be required for a materially different dosage form or delivery system.
• New commercial value depends on tolerability, application experience, adherence, packaging, and clinical differentiation.
• Patent strength is likely to be weak for legacy gel compositions and stronger for novel delivery systems, validated formulation parameters, and clinically supported methods of use.

FAQs

Can propylene glycol be removed from fluocinide gel without reducing efficacy?

Yes, but removal can change fluocinide solubility, drug release, viscosity, and skin permeation. The replacement system requires comparative formulation and performance testing.

Is fluocinide gel appropriate for facial or intertriginous use?

High-potency corticosteroids are generally used cautiously on thin skin, the face, groin, and skin folds because of increased local adverse-effect risk. Product labeling should control any proposed indication.[1]

Can a fluocinide gel obtain three years of FDA exclusivity?

A qualifying 505(b)(2) product may obtain three years of exclusivity if approval relies on new clinical investigations essential to approval. A routine ANDA does not create new clinical exclusivity.

Does an alcohol-free fluocinide gel require new clinical trials?

The requirement depends on the formulation change, regulatory pathway, and whether existing data adequately support equivalence, safety, and effectiveness. A materially different dosage form or delivery system may require clinical or pharmacokinetic evidence.

Is a fluocinide gel device patent commercially valuable?

It can be valuable if the device controls dose, improves delivery to a difficult anatomical site, or produces a clinically meaningful adherence benefit. A device patent without measurable product differentiation is less likely to create durable market protection.

References

1. U.S. Food and Drug Administration. (n.d.). Fluocinonide topical gel prescribing information. DailyMed.
2. National Library of Medicine. (n.d.). Fluocinonide gel, 0.05%: Inactive ingredients and labeling information. DailyMed.
3. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
5. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Product-specific guidance for industry. FDA.